These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
776 related articles for article (PubMed ID: 33162029)
1. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029 [TBL] [Abstract][Full Text] [Related]
2. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma. Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664 [TBL] [Abstract][Full Text] [Related]
3. Mitochondrial GCN5L1 acts as a novel regulator for iron homeostasis to promote sorafenib sensitivity in hepatocellular carcinoma. Hu X; Zhang P; Li S; Zhang J; Wang D; Wang Z; Zhu L; Wang L J Transl Med; 2024 Jun; 22(1):593. PubMed ID: 38918793 [TBL] [Abstract][Full Text] [Related]
4. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells. Tang H; Chen D; Li C; Zheng C; Wu X; Zhang Y; Song Q; Fei W Int J Pharm; 2019 Dec; 572():118782. PubMed ID: 31678528 [TBL] [Abstract][Full Text] [Related]
5. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Li ZJ; Dai HQ; Huang XW; Feng J; Deng JH; Wang ZX; Yang XM; Liu YJ; Wu Y; Chen PH; Shi H; Wang JG; Zhou J; Lu GD Acta Pharmacol Sin; 2021 Feb; 42(2):301-310. PubMed ID: 32699265 [TBL] [Abstract][Full Text] [Related]
6. Glycyrrhizic acid attenuates sorafenib resistance by inducing ferroptosis via targeting mTOR signaling in hepatocellular carcinoma. Hu Y; Luo Z; Cai S; Xie Q; Zheng S Scand J Gastroenterol; 2024 Jun; 59(6):730-736. PubMed ID: 38426342 [TBL] [Abstract][Full Text] [Related]
7. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Wang Q; Bin C; Xue Q; Gao Q; Huang A; Wang K; Tang N Cell Death Dis; 2021 Apr; 12(5):426. PubMed ID: 33931597 [TBL] [Abstract][Full Text] [Related]
8. Cotreatment with sorafenib and oleanolic acid induces reactive oxygen species-dependent and mitochondrial-mediated apoptotic cell death in hepatocellular carcinoma cells. Liese J; Hinrichs TM; Lange M; Fulda S Anticancer Drugs; 2019 Mar; 30(3):209-217. PubMed ID: 30640794 [TBL] [Abstract][Full Text] [Related]
9. DDX39B protects against sorafenib-induced ferroptosis by facilitating the splicing and cytoplasmic export of GPX4 pre-mRNA in hepatocellular carcinoma. Li Q; Yuan H; Zhao G; Ou D; Zhang J; Li L; Li S; Feng T; Gu R; Kou Q; Wang Q; Li S; Wang G; Zhao M; Yu H; Qu J; Lin P; Li K Biochem Pharmacol; 2024 Jul; 225():116251. PubMed ID: 38701867 [TBL] [Abstract][Full Text] [Related]
10. PLAG1 interacts with GPX4 to conquer vulnerability to sorafenib induced ferroptosis through a PVT1/miR-195-5p axis-dependent manner in hepatocellular carcinoma. Li J; Li Y; Wang D; Liao R; Wu Z J Exp Clin Cancer Res; 2024 May; 43(1):143. PubMed ID: 38745179 [TBL] [Abstract][Full Text] [Related]
11. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma. Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706 [TBL] [Abstract][Full Text] [Related]
12. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells. Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922 [TBL] [Abstract][Full Text] [Related]
13. SLC27A5 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by downregulating glutathione reductase. Xu FL; Wu XH; Chen C; Wang K; Huang LY; Xia J; Liu Y; Shan XF; Tang N Cell Death Dis; 2023 Jan; 14(1):22. PubMed ID: 36635256 [TBL] [Abstract][Full Text] [Related]
14. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells. Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082 [TBL] [Abstract][Full Text] [Related]
15. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling. Qian B; Che L; Du ZB; Guo NJ; Wu XM; Yang L; Zheng ZX; Gao YL; Wang MZ; Chen XX; Xu L; Zhou ZJ; Lin YC; Lin ZN Theranostics; 2023; 13(12):4288-4302. PubMed ID: 37554285 [No Abstract] [Full Text] [Related]
16. Phosphorylated FOXQ1, a novel substrate of JNK1, inhibits sorafenib-induced ferroptosis by activating ETHE1 in hepatocellular carcinoma. Liu Y; Shao K; Yang W; Shen Q; Lu M; Shao Z; Chu S; Wang Y; Wang X; Chen X; Bai J; Wu X Cell Death Dis; 2024 Jun; 15(6):395. PubMed ID: 38839744 [TBL] [Abstract][Full Text] [Related]
17. Activation of ferritinophagy is required for the RNA-binding protein ELAVL1/HuR to regulate ferroptosis in hepatic stellate cells. Zhang Z; Yao Z; Wang L; Ding H; Shao J; Chen A; Zhang F; Zheng S Autophagy; 2018; 14(12):2083-2103. PubMed ID: 30081711 [TBL] [Abstract][Full Text] [Related]
18. Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2. Elkateb AS; Nofal S; Ali SA; Atya HB Inflammation; 2023 Aug; 46(4):1493-1511. PubMed ID: 37171695 [TBL] [Abstract][Full Text] [Related]
19. Exosome-derived circUPF2 enhances resistance to targeted therapy by redeploying ferroptosis sensitivity in hepatocellular carcinoma. Dong FL; Xu ZZ; Wang YQ; Li T; Wang X; Li J J Nanobiotechnology; 2024 May; 22(1):298. PubMed ID: 38811968 [TBL] [Abstract][Full Text] [Related]
20. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]